Single-cell transcriptomics and chromatin accessibility profiling elucidate the kidney-protective mechanism of

Amin Abedini1,2,3, Andrea Sánchez-Navaro1,2,3, Junnan Wu1,2,3

  • 1Renal, Electrolyte, and Hypertension Division, Department of Medicine.

Insights

Mineralocorticoid excess drives hypertension and kidney disease. Finerenone and other treatments protect kidneys, with finerenone showing unique benefits for podocytes and tubules.

Area of Science:

  • Nephrology
  • Endocrinology
  • Genomics

Background:

  • Mineralocorticoid excess is a key driver of hypertension and kidney disease.
  • Understanding mineralocorticoid target cells and genes is crucial for developing effective therapies.

Purpose of the Study:

  • To characterize mineralocorticoid target genes and cell types using multiomics.
  • To evaluate the kidney-protective effects of mineralocorticoid receptor antagonists (MRAs) and amiloride in a rat model of hypertension-induced cardiorenal damage.

Main Methods:

  • Single-cell RNA sequencing and ATAC-seq to identify mineralocorticoid-regulated genes and chromatin accessibility.
  • A rat model of deoxycorticosterone acetate-induced hypertension, unilateral nephrectomy, and high-salt diet.
  • Assessment of cardiorenal damage, albuminuria, and gene expression profiles.

Main Results:

  • Mineralocorticoid effects are concentrated in principal and connecting tubule cells, with some in distal convoluted tubule cells.
  • All tested antihypertensive therapies (MRAs, amiloride) protected against cardiorenal damage.
  • Finerenone demonstrated superior efficacy in reducing albuminuria and improving gene expression in podocytes and proximal tubule cells, independent of blood pressure reduction.

Conclusions:

  • Mineralocorticoid excess impacts specific kidney tubule segments.
  • A gene signature (Spp1, Il34, Pdgfb) in injured tubule cells correlates with kidney fibrosis and may aid in classifying human kidney disease.
  • This study provides novel insights into hypertension-associated kidney disease mechanisms and the therapeutic potential of MRAs.

Related Concept Videos

Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
595
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
438
Renal Regulation of Acid-Base Balance01:29

Renal Regulation of Acid-Base Balance

Metabolic reactions in the body produce nonvolatile acids, such as sulfuric acid, which generate an acid load of approximately 1 mEq of H+ per kilogram of body weight daily. Excreting H+ in the urine is essential to balance this acid load.
In the kidneys, cells within the proximal convoluted tubules (PCT) and the collecting ducts secrete hydrogen ions (H+) into the tubular fluid. Specifically, in the PCT, Na+/H+ antiporters secrete H+ while reabsorbing Na+.
However, the intercalated cells in...
482
Renal Drug Excretion: Tubular Secretion01:28

Renal Drug Excretion: Tubular Secretion

Active tubular secretion is a robust, energy-demanding process that utilizes carrier systems to transport drugs into renal tubules. The active renal secretion systems include the organic anion transporter (OAT) for weak acids and the organic cation transporter (OCT) for weak bases. Structurally similar drugs can compete for the same transporter, potentially leading to drug accumulation and toxicity. However, this principle can be exploited therapeutically. One example is probenecid (Probalan),...
196
Renal Drug Excretion: Tubular Reabsorption01:25

Renal Drug Excretion: Tubular Reabsorption

Tubular reabsorption, a process occurring post-glomerular filtration of drugs in the renal tubule, is a critical determinant of drug half-life. During the process of renal excretion, as the glomerular filtrate progresses to the distal convoluted tubule (DCT), drugs that are highly permeable, lipophilic, and nonionized undergo passive reabsorption from the tubular fluid into the surrounding peritubular capillaries. This reabsorption process restricts their elimination through the kidneys. This...
193
Renal Corpuscle01:20

Renal Corpuscle

The glomerulus and Bowman's capsule are two essential components of the nephron, which is the functional unit of the kidney. These microscopic structures play a critical role in the process of blood filtration to produce urine.
Glomerulus: Structure and Function
The glomerulus is a tiny, intricate network of capillaries located at the beginning of the nephron. It's enveloped by the Bowman's capsule and receives its blood supply from an afferent arteriole, which divides into numerous...
2.4K